 |
| Tuberculosis Drugs |
Tuberculosis Drugs kill TB bacteria and help the immune system eliminate them. These medications are not without side effects, however, and the occurrence of these varies from person to person. Doctors monitor the patient during treatment to check that the medication is working, and it there are any side effects. In case of any side effects that are persistent or severe, doctors prescribe other medication.
The global Tuberculosis
Drugs Market was valued at US$
1,146.5 million in 2019 and is expected to exhibit a CAGR of 5.3% over the
forecast period (2019 – 2027).
The standard anti-TB drug regimen is effective at treating
most TB infections and has saved millions of lives. It is long and
complicated, requiring patients to take multiple drugs for six months under directly
observed therapy. It is not easy to keep up with, especially for people living
in the developing world. Inconsistent adherence to the regimen contributes to
the rise of Tuberculosis Drugs resistance, which
threatens the effectiveness of all current anti-TB medicines. India
Immuno-Oncology Drugs Market is estimated to be valued at US$ 265 Mn in
2021 and is expected to exhibit a CAGR of 13.1% during the forecast period
(2021 -2028).
In order to prevent the development of TB drug resistance,
national TB treatment guidelines recommend that every patient with active TB
disease receive directly observed therapy (DOT). Under this program, a trained
health worker accompanies each TB patient on their treatment journey and
ensures they swallow all of their prescribed drugs, at the proper times. This
is known as “watchful adherence.” While it cannot fully prevent Tuberculosis
Drugs
resistance, DOT has proven to be an effective approach for improving patient
adherence and reducing TB disease transmission. There are also several newer TB
drugs, which may shorten the length of a treatment regimen. These include fluoroquinolones, which have been shown to be bactericidal and sterilizing in
TB patients. The newer antibiotics, delamanid and bedaquiline, have also been
shown to have bactericidal and sterilizing activity in patients with TB.
In the case of latent TB infection (LTBI), a doctor will
prescribe medication to prevent the bacteria from reactivating into active TB.
Most often, this is Isoniazid (INH) or rifapentine. INH is the most common
antibiotic, and it is usually consumed daily for 9 months under a doctor’s
supervision. Rifapentine is an alternative to INH for people with certain risk
factors for TB reactivation. Be The Change For TB, a youth-focused, digital
initiative was launched by Johnson & Johnson India in March 2022. This is a
joint venture is aiming to eliminate Tuberculosis from the nation.